Cosibelimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cosibelimab. Educational only — not medical advice.
Labeled uses
UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Source: FDA labeling via NIH DailyMed (set 06bdadd5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.